4.1.3 Clinical Practice 26 4.2 China 32
5 Competitive Assessment 34 5.1 Overview 34 5.2 Product Profiles 35 5.2.1 Restasis ( cyclosporine ) 35 5.2.2 Diquas ( diquafosol tetrasodium ) 45 5.2.3 Mucosta ophthalmic solution ( rebamipide ) 51 5.2.4 Ikervis ( cyclosporine ) 56 5.2.5 Artificial Tears 63 5.2.6 Other therapies 71
Browse Complete Summary Click Here @ http :// www . radiantinsights . com / research / dry-eyesyndrome-china-drug-forecast-and-market-analysis-to-2024
6 Unmet Need and Opportunity 76 6.1 Overview 76 6.2 New Therapies for DES 78 6.2.1 Unmet Need 78 6.2.2 Gap Analysis 79 6.2.3 Opportunity 81 6.3 Better Diagnostic Tools 82 6.3.1 Unmet Need 82 6.3.2 Gap Analysis 83
6.3.3 Opportunity 85 6.4 Appropriate Clinical Trial Design to Secure Regulatory Approval 86 6.4.1 Unmet Need 86